Explore how evolving science, expanding global demand, and next-generation innovations are reshaping the future of corticosteroid and hormonal therapies — and what this transformation means for the years ahead.
Formulation Development White Papers & Articles
-
A Patented Process For Intermediates Useful For Upadacitinib
2/18/2026
Discover how innovative and safer synthetic strategies can streamline the manufacture of Upadacitinib while addressing the complexity and safety challenges inherent in its key intermediates.
-
Corticosteroids And Hormonal Therapies — History, Use, And Future Outlook
2/18/2026
-
Redefining OSD Development Through Foresight And Innovation
2/12/2026
From early formulation challenges to scale-up and commercial readiness, proactive planning and integrated capabilities help teams anticipate risks, accelerate decision-making, and maintain momentum across development.
-
Right From The Start: Smarter Developability For Stronger Formulations
2/4/2026
Early developability assessment integrates manufacturability, QbD, flexible formulations, and CDMO support to cut risk, speed development, and enable scalable, robust drugs.
-
NGS In GMP Manufacturing: Reducing Risk, Increasing Return
1/29/2026
Global regulators now recognize NGS as a rigorous, GMP‑ready tool for viral safety, driving a shift toward scalable quality strategies. Learn why NGS is becoming central to modern manufacturing.
-
A Word With Susan Li, Peptide Chief Scientist, Asymchem
1/29/2026
An overview of emerging TIDES innovations, from greener synthesis to digital tools that boost control, efficiency, scalability, and reliability across complex development workflows.
-
Selecting A CDMO For Custom Activated PEGs
1/27/2026
Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.
-
Assessing Developability And Designing Advanceable Formulations From The Start
1/15/2026
Discover how early developability assessments and a quality-by-design approach can streamline formulation, reduce risk, and accelerate your path to successful, cost-effective drug development.
-
Navigating Emerging Therapeutics: Cannabinoid And Psilocybin Drug Development
1/15/2026
Cannabinoid and psilocybin therapies are advancing rapidly, and Mikart supports innovators with DEA-licensed facilities, formulation expertise, regulatory guidance, and manufacturing capabilities from clinical development to commercialization.
-
Improving Swallowing And Palatability With Patient‑Friendly Forms
1/15/2026
Improve medication adherence and health outcomes by developing patient-friendly dosage forms that enhance swallowability and palatability for pediatric, geriatric, and dysphagic populations.